<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma - Concepedia

Concepedia

Publication | Open Access

<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma

DOI Full Paper Access

38

Citations

23

References

2021

Year

Niklas Klümper, Damian J. Ralser, Romina Zarbl, Katrin Schlack, Andres Jan Schrader, Marc Rehlinghaus, Michèle J. Hoffmann, Günter Niegisch, Annemarie Uhlig, Lutz Trojan,

Journal for ImmunoTherapy of Cancer

Abstract

Our study suggests <i>CTLA4</i> methylation as a powerful predictive biomarker for immunotherapy response in metastatic RCC.

References

	Year	Citations

Page 1